Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) Income from Non-Controlling Interests (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 6 years of Income from Non-Controlling Interests data on record, last reported at -$2.5 million in Q3 2025.

  • For Q3 2025, Income from Non-Controlling Interests rose 57.87% year-over-year to -$2.5 million; the TTM value through Sep 2025 reached -$19.3 million, up 27.91%, while the annual FY2024 figure was -$26.6 million, 21.66% up from the prior year.
  • Income from Non-Controlling Interests reached -$2.5 million in Q3 2025 per RANI's latest filing, up from -$4.5 million in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at -$2.5 million in Q3 2025 and bottomed at -$25.6 million in Q3 2021.
  • Average Income from Non-Controlling Interests over 5 years is -$7.9 million, with a median of -$7.3 million recorded in 2024.
  • The widest YoY moves for Income from Non-Controlling Interests: up 67.71% in 2022, down 52.09% in 2022.
  • A 5-year view of Income from Non-Controlling Interests shows it stood at -$8.1 million in 2021, then dropped by 5.42% to -$8.6 million in 2022, then grew by 18.69% to -$7.0 million in 2023, then grew by 2.62% to -$6.8 million in 2024, then soared by 63.07% to -$2.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Non-Controlling Interests were -$2.5 million in Q3 2025, -$4.5 million in Q2 2025, and -$5.5 million in Q1 2025.